Clinical trials: IV Injection
Complicated Skin and Skin Structure Infections, Complicated Intra-abdominal Infections
Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.
- Trial name
- NCT00683332
- Testing
- Tigecycline (Tygacil)
- Where
- Philippines
- Volunteers
- 621 people
- Sponsor
- Pfizer
Respiratory Tract Infections, Urinary Tract Infections
Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
- Trial name
- PIP-SBT (NCT01760109)
- Testing
- Piperacillin Sodium and Sulbactam Sodium
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Breast Cancer
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated…
- Trial name
- NCT00706615
- Testing
- Ad-sig-hMUC-1/ecdCD40L vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Normal Healthy Volunteers
Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV
This is a phase 1, safety and PK Open-Label trial evaluating the plasma, epithelial lining fluid, and alveolar macrophage concentrations of intravenous Minocin® (Minocycline) for injection in healthy adult subjects.
- Trial name
- NCT03291158
- Testing
- Minocycline
- Where
- Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Age-Related Macular Degeneration
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or…
- Trial name
- NCT00134667
- Testing
- Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Eyetech Pharmaceuticals
Hepatitis C, HIV Infections
Study to Reduce Intravenous Exposures (STRIVE)
The purpose of this study is to determine whether a six-session, small group behavioral intervention based on "peer-volunteer activism" is effective in (1) decreasing distributive sharing of syringes and other injection…
- Trial name
- NCT00391482
- Testing
- Peer Mentoring Intervention for HCV-Infected IDUs
- Where
- 3 sites in United States
- Volunteers
- 750 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Neovascular Age-related Macular Degeneration
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
- Trial name
- SALT (NCT01958918)
- Testing
- Ranibizumab, Aflibercept
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 712 people
- Sponsor
- Novartis Pharmaceuticals
Intravenous Administration
Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement
The purpose of this study is to compare the anxiety and pain levels of patients when using Buzzy with ice, Vapocoolant, and placebo when inserting IV's line for IV fluids and/or phlebotomy in pediatric patients in the pediatric…
- Trial name
- NCT06182631
- Testing
- Buzzy Bee, Vapocoolent
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.
- Trial name
- NCT00117351
- Testing
- VELCADE
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor
A Study of Injection HB002.1T in Subjects With Solid Tumor
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth…
- Trial name
- NCT03636750
- Testing
- HB002.1T
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Postburn Scars; Posttraumatic Scars, Atrophic Scar
Autologous Nanofat for Treatment of Atrophic Scars
A prospective, randomized, split-scar, within-participant controlled clinical study evaluating the efficacy and safety of a single session of autologous nanofat injection followed by topical silicone gel in the treatment of…
- Conditions
- Postburn Scars; Posttraumatic Scars, Atrophic Scar, Scar
- Trial name
- NCT07763275
- Testing
- Autologous Nanofat Injection, Topical
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Benha University
Hemophilia A
Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII
The ability of a new recombinant porcine coagulation factor VIII, B-domain deleted (called "OBI-1"), to control the non-life- or limb-threatening bleeding episodes patients with hemophilia A commonly develop is being evaluated.
- Trial name
- NCT00245245
- Testing
- recombinant porcine coagulation factor VIII (OBI-1)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Octagen Corporation
Healthy
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and safety of BCD-066 (darbepoetin alfa manufactured by CJSC BIOCAD, Russia) and Aranesp® (Amgen Europe B.V., Netherlands) in healthy…
- Trial name
- NCT02506881
- Testing
- Darbepoetin alfa
- Where
- Russia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biocad
Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer.
- Conditions
- Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH Wildtype
- Trial name
- NCT07648823
- Testing
- [177Lu]Lu-XT771
- Where
- 2 sites in China
- Volunteers
- 5 people
- Sponsor
- Beijing Tiantan Hospital
IV Injection
Compatibility Problems and Prescribing Pattern of Injectable Drugs at the Hospital
Drug safety is always a national, as well as international, patient safety goal. Administration of injection, especially intravenous infusion, is an extremely complicated and dangerous process, which includes reconstitution…
- Trial name
- NCT04523259
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Melanoma
Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response
The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body.
- Trial name
- NCT00680589
- Testing
- injection of mouse TYRP2 DNA
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy Volunteers
First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects
This Phase I first-in-human is designed to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of M201-A administered by single continuous intravenous injection in Healthy Japanese subjects.
- Trial name
- NCT03055403
- Testing
- M201-A Injection
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yuji KUMAGAI
Premature Ovarian Insufficiency
Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).
- Trial name
- NCT07775391
- Testing
- hUC-MSCs Injection (Phase I), hUC-MSCs Injection (Phase IIa)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Primary Immune Thrombocytopenia (ITP)
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
It is a clinical trial of a medicinal product Human Immunoglobulin for Intravenous Injection (5%) manufactured by Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as 5% IVIG).
- Trial name
- NCT07233213
- Testing
- Human immunoglobulin (pH4) for intravenous injection
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Grand Shuyang Life Sciences (Chengdu) Co., Ltd.